See new source-reviewed developments and what changed in the questions you watch. Empty means nothing meaningful moved.
The research todaySun, Oct 11
What moved.
What needs checking.
Since You Were Here
Watch what matters. Return here to see reviewed changes in the things you Watch.
Your Watching →What moved
No new reviewed changes to show.
We publish movement when receipts support it. Explore the questions still open below.
The Gap
Attention is why people are talking. Confidence is what the evidence lets us say for a claim.
No current reviewed attention receipts to compare yet.
Explore Trending →Open Questions
AbaloparatideFor adults with osteoporosis, how would Abaloparatide compare with an appropriate control on fractures and serious adverse events over two years?
→Beta-alanineFor adults undertaking exercise, how would Beta-alanine compare with an appropriate control on reproducible exercise performance over six months?
→BimagrumabFor adults with obesity, how would Bimagrumab compare with an appropriate control on physical function alongside body composition over one year?
→BPC-157For adults with musculoskeletal injury, how would BPC-157 compare with an appropriate control on validated recovery and serious adverse events over six months?
→All Open Questions →Research records to explore
Available catalog records. Inclusion here does not establish effectiveness, safety or an attention trend.
compound
Abaloparatide
1 linked source · Evidence assessment not publishedtopic
Absorptiometry, Photon
1 linked source · Evidence assessment not publishedcompound
Acarbose
1 linked source · Evidence assessment not publishedcompound
Acetyl-L-carnitine
1 linked source · Evidence assessment not publishedcompound
Afamelanotide
1 linked source · Evidence assessment not publishedcompound
AICAR
1 linked source · Evidence assessment not publishedcompound
Albiglutide
1 linked source · Evidence assessment not publishedcompound